Scholar Rock Holding Corp. (SRRK)

Scholar Rock's shares fell due to a potential delay in an important submission after the FDA tagged Catalent Indiana as "Official Action Indicated". The FDA rejected the company's biologics license application (BLA) for its apitegromab spinal muscular atrophy (SMA) drug. The company reported earnings per share (EPS) of ($0.98) for the quarter, missing the consensus estimate of ($0.66) by ($0.32). David L. Hallal was appointed as Chief Executive Officer. The stock was popular among investors following a positive new analyst note. Scholar Rock Holding Corp (SRRK) reported promising clinical results and strategic preparations for the launch of apitegromab. An upgrade in rating for Scholar Rock was noted, citing apitegromab approval and an obesity shot.

The provided search results do not contain specific information regarding demand seasonality for Scholar Rock Holding Corp.'s products and services. Its revenue and demand are primarily driven by the successful development and regulatory approval of its drug candidates, rather than typical seasonal consumer demand.

Scholar Rock Holding Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases related to protein growth factors, operating within the biotechnology and pharmaceutical industries, targeting the molecular mechanisms of growth factors in the extracellular matrix. Its major product candidates include Apitegromab, a monoclonal antibody for spinal muscular atrophy (SMA), SRK-439, an anti-myostatin antibody program targeting obesity and cardiometabolic disorders, and preclinical programs in fibrosis and oncology, targeting growth factors like TGF-beta.

Scholar Rock Holding Corp. is based in Cambridge, Massachusetts, and primarily operates locally within the United States.

Specific information detailing Scholar Rock Holding Corp.'s brand reputation was not explicitly found. Regulatory setbacks with the FDA regarding apitegromab and the manufacturing facility inspection could negatively impact investor confidence. Positive clinical trial results and analyst upgrades would contribute positively to its reputation.

Scholar Rock Holding Corp. has significant institutional ownership, with 524 institutional owners and shareholders holding a total of 123,599,549 shares, representing approximately 91.08% of the company's stock. Major institutional owners include Fmr Llc, Price T Rowe Associates Inc /md/, BlackRock, Inc., Samsara BioCapital, LLC, Vanguard Group Inc, Redmile Group, LLC, State Street Corp, and Invus Public Equities LP. Srinivas Akkaraju is the largest individual shareholder, owning 16.04 million shares, representing 16.68% of the company. Insiders own approximately 23.39% of the company's stock.